Umeå-based Lipum will reach an important milestone in its history this year as clinical trials begin on its antibody to treat inflammatory diseases. No less than 17 consultants are now involved in the drug’s development.
Umeå-based biopharmaceutical company Lipum has been working towards a stock exchange listing since 2018 – and now the moment has finally arrived. On Thursday, April 22, shares in Lipum will be traded on the Nasdaq First North Growth Market for the very first time. The company will ring Nasdaq's opening bell, which has been specially transported to Umeå, to mark the occasion.
Umeå-based biopharmaceutical company Lipum AB is raising capital for a listing on the Nasdaq First North Growth Market in the spring of 2021. “We are taking the next exciting step in the company's development”, says Lipum’s CEO Einar Pontén.
Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.
Tvistevägen 48C
907 36 Umeå
Sweden